# Leveraging an academic-industry partnership to develop a cancer-specific mobile meditation app > **NIH NIH R41** · CALM.COM, INC. · 2021 · $397,657 ## Abstract 1 Project Summary/Abstract 2 Approximately 15.5 million US cancer patients/survivors experience a host of residual symptoms (e.g., 3 fatigue, anxiety, depression, pain, sleep disturbance) and reduced quality of life that are often not resolved with 4 even the best-available current standard of care therapies. Residual symptom burden impairs cancer survivor 5 functioning and leads to increased rates of disability and healthcare utilization, costing $125 billion every year. 6 Cancer patients/survivors want and need complementary strategies to accompany standard therapies. 7 Research has demonstrated the benefits of mindfulness-based therapies, such as meditation, for 8 alleviating cancer-related symptoms (e.g., fatigue, anxiety, depression, and sleep disturbance).Meditation-based 9 programs are typically conducted in-person, in clinic settings; however, these programs are expensive and 10 difficult to sustain, and cancer patients report barriers to participating (e.g., travel demands, fatigue, pain, and 11 scheduling difficulties). Smartphone-based meditation is a feasible and novel method for delivering meditation 12 to cancer patients/survivors. Mobile apps and online meditation programs have demonstrated short-term benefits 13 for cancer patients/survivors; however, the currently available commercial meditation apps are limited in their 14 engagement, acceptability, and applicability to cancer patients/survivors’ unique experiences and have not been 15 evaluated for feasibility or efficacy. There is an unmet need for a commercially-available, evidence-based 16 meditation app specifically designed for cancer patients/survivors. Incorporating stakeholder feedback (i.e., 17 patients and healthcare providers) in the early design phase will facilitate the development of a meditation app 18 truly targeted for the end users that can be made commercially available, thereby improving uptake and impact 19 in patient populations. Calm, a popular consumer-based meditation app with 70 million downloads and 2 million 20 subscribers, provides a platform from which to develop an accessible standalone cancer-specific meditation app. 21 This project will: 1) gather feedback about the current Calm app from an advisory committee (N=20) consisting 22 of cancer patients/survivors (n=10, 5 of each) and healthcare providers (n=10), 2) design a cancer-specific 23 meditation app prototype, and 3) beta-test the prototype in cancer patients/survivors (N=30). 24 A standalone meditation app designed for and tested by cancer patients/survivors, leveraging a popular 25 and validated meditation app platform, to be made commercially available, is innovative and could provide a 26 scalable, highly engaging symptom-management tool that addresses cancer patients/survivors’ unique needs. 27 If our key feasibility milestones are met, we will further refine the cancer-specific app and conduct a randomized 28 controlled trial to determine the app’s long-term efficacy in reducin... ## Key facts - **NIH application ID:** 10253517 - **Project number:** 1R41CA261260-01 - **Recipient organization:** CALM.COM, INC. - **Principal Investigator:** Jennifer Lynne Huberty - **Activity code:** R41 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2021 - **Award amount:** $397,657 - **Award type:** 1 - **Project period:** 2021-03-01 → 2022-06-30 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10253517 ## Citation > US National Institutes of Health, RePORTER application 10253517, Leveraging an academic-industry partnership to develop a cancer-specific mobile meditation app (1R41CA261260-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10253517. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*